The SAPIEN 3 platform addresses the key drivers of reintervention

Join Edwards Connect

Our exclusive portal grants you access to our latest educational tools, resources, and more to help you communicate with your patients and referrers.

Connect with us

The Edwards SAPIEN platform brochure

When it comes to lifetime management, learn more about how the Edwards SAPIEN 3 platform is designed to deliver a TAVR experience an implanter can count on, starting with the index procedure.

View the brochure

The Edwards SAPIEN 3 platform has demonstrated excellent durability

The PARTNER II S3i trial has demonstrated:
  • Transcatheter aortic valve replacement (TAVR) durability similar to surgery at five years2
  • Low rates of structural valve deterioration (SVD) and SVD-related bioprosthetic valve failure, similar to surgery at five years2
Real-world data has demonstrated:
  • Excellent five-year SAPIEN valve durability performance for small-annuli patients3

The SAPIEN 3 Ultra valve, powered by RESILIA tissue technology

  • Advanced calcium-blocking tissue technology4‡
  • Same tissue technology used in the #1 implanted surgical valve in the U.S.
  • Potential to improve valve longevity and reduce reintervention‡∥
  • The only commercially available transcatheter heart valve with dry tissue storage
Explore clinical data for RESILIA tissue

No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients.
RESILIA tissue tested against tissue from commercially available bovine pericardial valves from Edwards Lifesciences in a juvenile sheep model. Flameng W, et al. J Thorac Cardiovasc Surg. 2015;149 (1):340-345.

Edwards SAPIEN platform: The leading solution for lifetime management

Every patient—across all valve sizes and genders—deserves to be considered for comprehensive lifetime management.

See the new real-world data

References:   1. Nazif TM, Cahill TJ, Daniels D, et al. Real-world experience with the SAPIEN 3 Ultra transcatheter heart valve: a propensity-matched analysis from the United States. Circ Interventions. 2021; 14:e010543. 2. Pibarot P, Ternacle J, Jaber WA, et al. Structural deterioration of transcatheter versus surgical aortic valve bioprosthesis in PARTNER-2 trial. J Am Coll Cardiol. 2020;76:1830-1843. 3. Okuno T, Tomii D, Lanz J, et al. 5-year outcomes with self-expanding vs balloon-expandable transcatheter aortic valve replacement in patients with small annuli. JACC Cardiovasc Interv. 2023;16(4):429-440. doi:10.1016/j.jcin.2022.11.032. 4. Flameng W, Hermans H, Verbeken E, et al. Randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. J Thorac Cardiovasc Surg. 2015;149(1):340-345.